Morgan Stanley Keros Therapeutics, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 878,746 shares of KROS stock, worth $12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

878,746

Previous 1,697,557 48.23%

Holding current value

$12 Million

Previous $17.3 Million 32.18%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$9.55 - $15.11 $7.82 Million - $12.4 Million	-818,811 Reduced 48.23%	878,746 $11.7 Million
Q1 2025 May 15, 2025	BUY	$10.15 - $16.1 $10.6 Million - $16.8 Million	1,040,756 Added 158.46%	1,697,557 $17.3 Million
Q4 2024 Feb 14, 2025	BUY	$15.64 - $70.0 $4.56 Million - $20.4 Million	291,504 Added 79.8%	656,801 $10.4 Million
Q3 2024 May 14, 2025	BUY	$41.68 - $58.07 $1.23 Million - $1.72 Million	29,628 Added 8.83%	365,297 $21.2 Million
Q3 2024 Nov 14, 2024	BUY	$41.68 - $58.07 $1.23 Million - $1.72 Million	29,628 Added 8.83%	365,297 $21.2 Million
Q2 2024 May 14, 2025	SELL	$44.58 - $66.89 $14.3 Million - $21.5 Million	-321,132 Reduced 48.89%	335,669 $15.3 Million
Q2 2024 Oct 17, 2024	BUY	$44.58 - $66.89 $2.07 Million - $3.11 Million	46,512 Added 16.09%	335,669 $15.3 Million
Q2 2024 Aug 14, 2024	BUY	$44.58 - $66.89 $2.07 Million - $3.11 Million	46,512 Added 16.09%	335,669 $15.3 Million
Q1 2024 Oct 17, 2024	SELL	$41.26 - $70.48 $1.92 Million - $3.28 Million	-46,512 Reduced 13.86%	289,157 $19.1 Million
Q1 2024 Aug 16, 2024	SELL	$41.26 - $70.48 $26.3 Million - $44.8 Million	-636,231 Reduced 68.75%	289,157 $19.1 Million
Q1 2024 May 15, 2024	SELL	$41.26 - $70.48 $26.3 Million - $44.8 Million	-636,231 Reduced 68.75%	289,157 $19.1 Million
Q4 2023 Aug 16, 2024	BUY	$27.12 - $41.05 $16 Million - $24.2 Million	589,719 Added 175.68%	925,388 $36.8 Million
Q4 2023 Feb 13, 2024	BUY	$27.12 - $41.05 $12.9 Million - $19.6 Million	476,687 Added 106.24%	925,388 $36.8 Million
Q3 2023 Nov 15, 2023	BUY	$31.57 - $43.02 $12.6 Million - $17.2 Million	398,903 Added 801.04%	448,701 $14.3 Million
Q2 2023 Aug 14, 2023	SELL	$37.26 - $51.01 $3.4 Million - $4.65 Million	-91,172 Reduced 64.67%	49,798 $2 Million
Q1 2023 May 15, 2023	SELL	$41.44 - $59.32 $82,507 - $118,106	-1,991 Reduced 1.39%	140,970 $6.02 Million
Q4 2022 Feb 14, 2023	BUY	$39.45 - $51.77 $3.21 Million - $4.22 Million	81,440 Added 132.38%	142,961 $6.86 Million
Q3 2022 Nov 14, 2022	SELL	$27.8 - $40.12 $1.62 Million - $2.34 Million	-58,277 Reduced 48.65%	61,521 $2.31 Million
Q2 2022 Oct 27, 2022	BUY	$26.03 - $67.04 $1.77 Million - $4.56 Million	67,970 Added 131.15%	119,798 $3.31 Million
Q2 2022 Aug 15, 2022	BUY	$26.03 - $67.04 $1.77 Million - $4.56 Million	67,970 Added 131.15%	119,798 $3.31 Million
Q1 2022 Oct 27, 2022	SELL	$42.12 - $59.36 $2.86 Million - $4.03 Million	-67,970 Reduced 56.74%	51,828 $2.82 Million
Q1 2022 May 13, 2022	BUY	$42.12 - $59.36 $1.88 Million - $2.65 Million	44,687 Added 625.78%	51,828 $2.82 Million
Q4 2021 Feb 14, 2022	SELL	$36.95 - $62.89 $2.7 Million - $4.6 Million	-73,071 Reduced 91.1%	7,141 $417,000
Q3 2021 Nov 15, 2021	BUY	$29.27 - $43.71 $2.35 Million - $3.51 Million	80,212 New	80,212 $3.17 Million

Others Institutions Holding KROS

# of Institutions

155

Shares Held

38.6M

Call Options Held

834K

Put Options Held

969K

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $353M
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account